Physician profile
Adrienne Keely
NPI 1912454828
$3,218.47
in general payments reported to CMS, 2019-2025
21 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.06 · 2022: $177 · 2023: $662 · 2024: $841 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.79 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.82 | 2022-2025 | |
| Janssen Biotech, INC. | $485.67 | 2023-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $267.32 | 2024-2025 | |
| Ucb, INC. | $206.89 | 2025 | Bimzelx |
| Incyte Corporation | $206.22 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $199.09 | 2022-2025 | Nemluvio |
| Leo Pharma INC. | $189.81 | 2023-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $186.17 | 2025 | Dupixent, Libtayo |
| Amgen INC. | $124.42 | 2022-2024 | Otezla |
| Organogenesis INC. | $120.30 | 2023-2025 | Puraply, Apligraf |
| Novartis Pharmaceuticals Corporation | $106.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.03 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $77.71 | 2023-2025 | Odomzo, Blu-U |
| Pfizer INC. | $65.92 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $56.74 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $54.88 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Arcutis Biotherapeutics, INC. | $33.71 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.38 | 2025 | Spevigo |
| Genentech USA, INC. | $19.69 | 2025 | Xolair |
| Biofrontera INC. | $19.01 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.35 | 2024 | Arazlo, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Keely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.